No Data
No Data
ADC Therapeutics SA (NYSE:ADCT) Held Back By Insufficient Growth Even After Shares Climb 26%
ADC THERAPEUTICS SA -REDH Earnings Preview: Recent $ADCT Insider Trading, Hedge Fund Activity, and More
Express News | Cantor Fitzgerald Reiterates Overweight on ADC Therapeuticsto Overweight
ADC Therapeutics Is Maintained at Overweight by Stephens & Co.
Stephens Maintains ADC Therapeutics(ADCT.US) With Buy Rating, Raises Target Price to $8
ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference